Brief: Glenmark Pharmaceuticals Approves Transfer Of Consumer Care Business To Unit
14/08/2025 13:34
Aug 14 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: APPROVES TRANSFER OF CONSUMER CARE BUSINESS TO SUBSIDIARY BUSINESS TRANSFER VALUED AT 2.40 BILLION RUPEES Source text: ID:nBSE9HGC1t Further company coverage: GLEN.NS ((Reutersbriefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter